ID   AGRIN_HUMAN             Reviewed;        2068 AA.
AC   O00468; Q5SVA1; Q5SVA2; Q60FE1; Q7KYS8; Q8N4J5; Q96IC1; Q9BTD4;
DT   25-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   12-SEP-2018, sequence version 6.
DT   18-JUN-2025, entry version 219.
DE   RecName: Full=Agrin;
DE   Contains:
DE     RecName: Full=Agrin N-terminal 110 kDa subunit;
DE   Contains:
DE     RecName: Full=Agrin C-terminal 110 kDa subunit;
DE   Contains:
DE     RecName: Full=Agrin C-terminal 90 kDa fragment;
DE              Short=C90;
DE   Contains:
DE     RecName: Full=Agrin C-terminal 22 kDa fragment;
DE              Short=C22;
DE   Flags: Precursor;
GN   Name=AGRN; Synonyms=AGRIN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6).
RC   TISSUE=Retinal pigment epithelium;
RA   Kato S.;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 20-2068 (ISOFORM 6), AND TISSUE SPECIFICITY.
RX   PubMed=9652404; DOI=10.1046/j.1432-1327.1998.2540123.x;
RA   Groffen A.J.A., Buskens C.A.F., Van Kuppevelt T.H., Veerkamp J.H.,
RA   Monnens L.A.H., Van den Heuvel L.P.W.J.;
RT   "Primary structure and high expression of human agrin in basement membranes
RT   of adult lung and kidney.";
RL   Eur. J. Biochem. 254:123-128(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 20-172 (ISOFORMS 1/3/4/5/6/7), AND
RP   INTERACTION WITH LAMININ.
RX   PubMed=9151673; DOI=10.1083/jcb.137.3.671;
RA   Denzer A.J., Brandenberger R., Gesemann M., Chiquet M., Ruegg M.A.;
RT   "Agrin binds to the nerve-muscle basal lamina via laminin.";
RL   J. Cell Biol. 137:671-683(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1558-2068 (ISOFORM 6), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1869-2068 (ISOFORM 3).
RC   TISSUE=Brain, Colon, and Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION OF TRANSMEMBRANE ISOFORM (ISOFORM 2).
RX   PubMed=11161480; DOI=10.1006/mcne.2000.0932;
RA   Neumann F.R., Bittcher G., Annies M., Schumacher B., Kroger S., Ruegg M.A.;
RT   "An alternative amino-terminus expressed in the central nervous system
RT   converts agrin to a type II transmembrane protein.";
RL   Mol. Cell. Neurosci. 17:208-225(2001).
RN   [7]
RP   IDENTIFICATION OF TRANSMEMBRANE ISOFORM (ISOFORM 2), ALTERNATIVE SPLICING,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=16487930; DOI=10.1016/j.bbrc.2006.01.161;
RA   Kumar P., Ferns M.J., Meizel S.;
RT   "Identification of agrinSN isoform and muscle-specific receptor tyrosine
RT   kinase (MuSK) in sperm.";
RL   Biochem. Biophys. Res. Commun. 342:522-528(2006).
RN   [8]
RP   ERRATUM OF PUBMED:16487930.
RA   Kumar P., Ferns M.J., Meizel S.;
RL   Biochem. Biophys. Res. Commun. 344:453-453(2006).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-135.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY, TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20551380; DOI=10.1074/mcp.m110.001693;
RA   Didangelos A., Yin X., Mandal K., Baumert M., Jahangiri M., Mayr M.;
RT   "Proteomics characterization of extracellular space components in the human
RT   aorta.";
RL   Mol. Cell. Proteomics 9:2048-2062(2010).
RN   [11]
RP   INTERACTION WITH LRP4, AND FUNCTION.
RX   PubMed=21969364; DOI=10.1074/jbc.m111.279307;
RA   Zhang W., Coldefy A.S., Hubbard S.R., Burden S.J.;
RT   "Agrin binds to the N-terminal region of Lrp4 protein and stimulates
RT   association between Lrp4 and the first immunoglobulin-like domain in
RT   muscle-specific kinase (MuSK).";
RL   J. Biol. Chem. 286:40624-40630(2011).
RN   [12]
RP   POTENTIAL USAGE AS A BIOMARKER FOR SARCOPENIA.
RX   PubMed=22683512; DOI=10.1016/j.exger.2012.05.021;
RA   Drey M., Sieber C.C., Bauer J.M., Uter W., Dahinden P., Fariello R.G.,
RA   Vrijbloed J.W.;
RT   "C-terminal Agrin Fragment as a potential marker for sarcopenia caused by
RT   degeneration of the neuromuscular junction.";
RL   Exp. Gerontol. 48:76-80(2013).
RN   [13]
RP   INVOLVEMENT IN CMS8, VARIANT CMS8 ARG-1709, VARIANTS LEU-23; ASN-58;
RP   ILE-105; MET-267; SER-375; VAL-728; ARG-852; MET-984; PHE-1088; LYS-1118;
RP   ARG-1135; LEU-1240; ARG-1341; LEU-1451; THR-1514; HIS-1565; ILE-1666;
RP   GLN-1671; PRO-1698; HIS-1734; ASN-1789 AND VAL-2046, FUNCTION, AND
RP   CHARACTERIZATION OF VARIANT CMS8 ARG-1709.
RX   PubMed=19631309; DOI=10.1016/j.ajhg.2009.06.015;
RA   Huze C., Bauche S., Richard P., Chevessier F., Goillot E., Gaudon K.,
RA   Ben Ammar A., Chaboud A., Grosjean I., Lecuyer H.A., Bernard V., Rouche A.,
RA   Alexandri N., Kuntzer T., Fardeau M., Fournier E., Brancaccio A.,
RA   Ruegg M.A., Koenig J., Eymard B., Schaeffer L., Hantai D.;
RT   "Identification of an agrin mutation that causes congenital myasthenia and
RT   affects synapse function.";
RL   Am. J. Hum. Genet. 85:155-167(2009).
RN   [14]
RP   ERRATUM OF PUBMED:19631309.
RA   Huze C., Bauche S., Richard P., Chevessier F., Goillot E., Gaudon K.,
RA   Ben Ammar A., Chaboud A., Grosjean I., Lecuyer H.A., Bernard V., Rouche A.,
RA   Alexandri N., Kuntzer T., Fardeau M., Fournier E., Brancaccio A.,
RA   Ruegg M.A., Koenig J., Eymard B., Schaeffer L., Hantai D.;
RL   Am. J. Hum. Genet. 85:536-536(2009).
RN   [15]
RP   VARIANT CMS8 PHE-1727, INTERACTION WITH DAG1, AND CHARACTERIZATION OF
RP   VARIANT CMS8 PHE-1727.
RX   PubMed=22205389; DOI=10.1007/s00439-011-1132-4;
RA   Maselli R.A., Fernandez J.M., Arredondo J., Navarro C., Ngo M., Beeson D.,
RA   Cagney O., Williams D.C., Wollmann R.L., Yarov-Yarovoy V., Ferns M.J.;
RT   "LG2 agrin mutation causing severe congenital myasthenic syndrome mimics
RT   functional characteristics of non-neural (z-) agrin.";
RL   Hum. Genet. 131:1123-1135(2012).
RN   [16]
RP   VARIANT VAL-745, VARIANTS CMS8 SER-76; ILE-105 AND ARG-1875, AND
RP   CHARACTERIZATION OF VARIANTS CMS8 SER-76 AND ILE-105.
RX   PubMed=24951643; DOI=10.1093/brain/awu160;
RA   Nicole S., Chaouch A., Torbergsen T., Bauche S., de Bruyckere E.,
RA   Fontenille M.J., Horn M.A., van Ghelue M., Loeseth S., Issop Y., Cox D.,
RA   Mueller J.S., Evangelista T., Staalberg E., Ioos C., Barois A.,
RA   Brochier G., Sternberg D., Fournier E., Hantai D., Abicht A., Dusl M.,
RA   Laval S.H., Griffin H., Eymard B., Lochmueller H.;
RT   "Agrin mutations lead to a congenital myasthenic syndrome with distal
RT   muscle weakness and atrophy.";
RL   Brain 137:2429-2443(2014).
CC   -!- FUNCTION: [Isoform 1]: Heparan sulfate basal lamina glycoprotein that
CC       plays a central role in the formation and the maintenance of the
CC       neuromuscular junction (NMJ) and directs key events in postsynaptic
CC       differentiation. Component of the AGRN-LRP4 receptor complex that
CC       induces the phosphorylation and activation of MUSK. The activation of
CC       MUSK in myotubes induces the formation of NMJ by regulating different
CC       processes including the transcription of specific genes and the
CC       clustering of AChR in the postsynaptic membrane. Calcium ions are
CC       required for maximal AChR clustering. AGRN function in neurons is
CC       highly regulated by alternative splicing, glycan binding and
CC       proteolytic processing. Modulates calcium ion homeostasis in neurons,
CC       specifically by inducing an increase in cytoplasmic calcium ions.
CC       Functions differentially in the central nervous system (CNS) by
CC       inhibiting the alpha(3)-subtype of Na+/K+-ATPase and evoking
CC       depolarization at CNS synapses. This secreted isoform forms a bridge,
CC       after release from motor neurons, to basal lamina through binding
CC       laminin via the NtA domain.
CC   -!- FUNCTION: [Isoform 2]: Transmembrane form that is the predominate form
CC       in neurons of the brain, induces dendritic filopodia and synapse
CC       formation in mature hippocampal neurons in large part due to the
CC       attached glycosaminoglycan chains and the action of Rho-family GTPases.
CC   -!- FUNCTION: Isoform 1, isoform 4 and isoform 5: neuron-specific (z+)
CC       isoforms that contain C-terminal insertions of 8-19 AA are potent
CC       activators of AChR clustering. Isoform 5, agrin (z+8), containing the
CC       8-AA insert, forms a receptor complex in myotubules containing the
CC       neuronal AGRN, the muscle-specific kinase MUSK and LRP4, a member of
CC       the LDL receptor family. The splicing factors, NOVA1 and NOVA2,
CC       regulate AGRN splicing and production of the 'z' isoforms.
CC   -!- FUNCTION: Isoform 3 and isoform 6: lack any 'z' insert, are muscle-
CC       specific and may be involved in endothelial cell differentiation.
CC   -!- FUNCTION: [Agrin N-terminal 110 kDa subunit]: Is involved in regulation
CC       of neurite outgrowth probably due to the presence of the
CC       glycosaminoglcan (GAG) side chains of heparan and chondroitin sulfate
CC       attached to the Ser/Thr- and Gly/Ser-rich regions. Also involved in
CC       modulation of growth factor signaling (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:19631309, ECO:0000269|PubMed:21969364}.
CC   -!- FUNCTION: [Agrin C-terminal 22 kDa fragment]: This released fragment is
CC       important for agrin signaling and to exert a maximal dendritic
CC       filopodia-inducing effect. All 'z' splice variants (z+) of this
CC       fragment also show an increase in the number of filopodia.
CC   -!- SUBUNIT: Monomer (By similarity). Interacts (N-terminal subunit) with
CC       TGF-beta family members, BMP2 and BMP4; the interactions inhibit the
CC       activity of these growth factors. Interacts with TGFB1; the interaction
CC       enhances the activity of TGFB1 (By similarity). Component of the AGRN-
CC       LRP4 complex that consists of a tetramer of two AGRN-LRP4 heterodimers.
CC       Interacts (via the laminin G-like 3 domain) directly with LRP4; the
CC       interaction is required for activation of MUSK and clustering of AChR
CC       and requires the 'z8' insert present in the z(+8) isoforms. Interacts
CC       with DAG1; the interaction is influenced by cell surface
CC       glycosaminoglycans and by alternative splicing of AGRN. {ECO:0000250,
CC       ECO:0000269|PubMed:21969364, ECO:0000269|PubMed:22205389,
CC       ECO:0000269|PubMed:9151673}.
CC   -!- INTERACTION:
CC       O00468; O15265: ATXN7; NbExp=2; IntAct=EBI-947482, EBI-708350;
CC       O00468-6; Q8N9W6-4: BOLL; NbExp=3; IntAct=EBI-17740588, EBI-11983447;
CC       O00468-6; Q9Y5V3: MAGED1; NbExp=3; IntAct=EBI-17740588, EBI-716006;
CC       O00468-6; Q96N21: TEPSIN; NbExp=3; IntAct=EBI-17740588, EBI-11139477;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Secreted, extracellular space,
CC       extracellular matrix {ECO:0000269|PubMed:20551380}. Note=Synaptic basal
CC       lamina at the neuromuscular junction. {ECO:0000250|UniProtKB:P31696}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Synapse
CC       {ECO:0000250|UniProtKB:A2ASQ1}. Cell membrane
CC       {ECO:0000250|UniProtKB:A2ASQ1}; Single-pass type II membrane protein
CC       {ECO:0000250|UniProtKB:A2ASQ1}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC         Comment=Many isoforms may exist depending on the occurrence and
CC         length of inserts at the x, y or z splice site. Four 'z' isoforms can
CC         be produced with inserts of 0, 8, 11 or 19 AA. Isoforms differ in
CC         their acetylcholine receptor clustering activity and tissue
CC         specificity.;
CC       Name=1; Synonyms=Secreted agrin, LN-agrin;
CC         IsoId=O00468-1; Sequence=Displayed;
CC       Name=2; Synonyms=Transmembrane agrin, TM-agrin;
CC         IsoId=O00468-2; Sequence=VSP_045753, VSP_045754;
CC       Name=3; Synonyms=Agrin z(0);
CC         IsoId=O00468-3; Sequence=VSP_045756;
CC       Name=4; Synonyms=Agrin z(+11);
CC         IsoId=O00468-4; Sequence=VSP_045757;
CC       Name=5; Synonyms=Agrin z(+8);
CC         IsoId=O00468-5; Sequence=VSP_045758;
CC       Name=6; Synonyms=Agrin y(0)z(0);
CC         IsoId=O00468-6; Sequence=VSP_045755, VSP_045756;
CC       Name=7; Synonyms=y(0);
CC         IsoId=O00468-7; Sequence=VSP_045755;
CC   -!- TISSUE SPECIFICITY: Expressed in basement membranes of lung and kidney.
CC       Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the
CC       4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-
CC       specific. Isoforms (z+11) are found in both neuronal and non-neuronal
CC       tissues. {ECO:0000269|PubMed:16487930, ECO:0000269|PubMed:20551380,
CC       ECO:0000269|PubMed:9652404}.
CC   -!- DOMAIN: The NtA domain, absent in TM-agrin, is required for binding
CC       laminin and connecting to basal lamina.
CC   -!- DOMAIN: Both laminin G-like 2 (G2) and laminin G-like 3 (G3) domains
CC       are required for alpha-dystroglycan/DAG1 binding. G3 domain is required
CC       for C-terminal heparin, heparan sulfate and sialic acid binding (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Contains heparan and chondroitin sulfate chains and alpha-
CC       dystroglycan as well as N-linked and O-linked oligosaccharides.
CC       Glycosaminoglycans (GAGs), present in the N-terminal 110 kDa fragment,
CC       are required for induction of filopodia in hippocampal neurons. The
CC       first cluster (Gly/Ser-rich) for GAG attachment contains heparan
CC       sulfate (HS) chains and the second cluster (Ser/Thr-rich), contains
CC       chondroitin sulfate (CS) chains. Heparin and heparin sulfate binding in
CC       the G3 domain is independent of calcium ions. Binds heparin with a
CC       stoichiometry of 2:1. Binds sialic acid with a stoichiometry of 1:1 and
CC       binding requires calcium ions (By similarity). {ECO:0000250}.
CC   -!- PTM: At synaptic junctions, cleaved at two conserved sites, alpha and
CC       beta, by neurotrypsin. Cleavage at the alpha-site produces the agrin N-
CC       terminal 110-kDa subunit and the agrin C-terminal 110-kDa subunit.
CC       Further cleavage of agrin C-terminal 110-kDa subunit at the beta site
CC       produces the C-terminal fragments, agrin C-terminal 90 kDa fragment and
CC       agrin C-terminal 22 kDa fragment. Excessive cleavage at the beta-site
CC       releases large amounts of the agrin C-terminal 22 kDa fragment leading
CC       to destabilization at the neuromuscular junction (NMJ).
CC   -!- DISEASE: Myasthenic syndrome, congenital, 8 (CMS8) [MIM:615120]: A form
CC       of congenital myasthenic syndrome, a group of disorders characterized
CC       by failure of neuromuscular transmission, including pre-synaptic,
CC       synaptic, and post-synaptic disorders that are not of autoimmune
CC       origin. Clinical features are easy fatigability and muscle weakness.
CC       CMS8 is an autosomal recessive disease characterized by prominent
CC       defects of both the pre- and postsynaptic regions. Affected individuals
CC       have onset of muscle weakness in early childhood; the severity of the
CC       weakness and muscles affected is variable.
CC       {ECO:0000269|PubMed:19631309, ECO:0000269|PubMed:22205389,
CC       ECO:0000269|PubMed:24951643}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Cleaved C-terminal fragments may be used as a biomarker
CC       for sarcopenia, age-related progressive loss of skeletal muscle.
CC       {ECO:0000305|PubMed:22683512}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by usage of an alternative first
CC       exon. {ECO:0000305}.
CC   -!- CAUTION: The unknown residue 'x' in the transmembrane isoform is
CC       probably a proline residue by similarity to mouse and rat sequences.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=The Leiden Muscular Dystrophy pages, Agrin (AGRN);
CC       Note=Leiden Open Variation Database (LOVD);
CC       URL="https://databases.lovd.nl/shared/genes/AGRN";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB191264; BAD52440.1; -; mRNA.
DR   EMBL; AL645608; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF016903; AAC39776.1; -; mRNA.
DR   EMBL; U84406; AAB52917.1; -; mRNA.
DR   EMBL; BC004220; AAH04220.2; -; mRNA.
DR   EMBL; BC007649; AAH07649.1; -; mRNA.
DR   EMBL; BC034009; AAH34009.1; -; mRNA.
DR   EMBL; BC063620; AAH63620.1; -; mRNA.
DR   CCDS; CCDS30551.1; -. [O00468-6]
DR   RefSeq; NP_001292204.1; NM_001305275.2. [O00468-1]
DR   RefSeq; NP_940978.2; NM_198576.3. [O00468-6]
DR   RefSeq; XP_005244806.1; XM_005244749.4. [O00468-3]
DR   RefSeq; XP_054192447.1; XM_054336472.1. [O00468-3]
DR   PDB; 8S9P; EM; 3.80 A; A=1-2068.
DR   PDBsum; 8S9P; -.
DR   AlphaFoldDB; O00468; -.
DR   EMDB; EMD-40241; -.
DR   SMR; O00468; -.
DR   BioGRID; 132000; 291.
DR   FunCoup; O00468; 416.
DR   IntAct; O00468; 51.
DR   MINT; O00468; -.
DR   STRING; 9606.ENSP00000368678; -.
DR   ChEMBL; CHEMBL4295648; -.
DR   TCDB; 8.A.74.1.3; the tm9 or phg1 targeting receptor (phg1) family.
DR   UniLectin; O00468; -.
DR   CarbonylDB; O00468; -.
DR   GlyConnect; 998; 17 N-Linked glycans (4 sites).
DR   GlyCosmos; O00468; 18 sites, 29 glycans.
DR   GlyGen; O00468; 52 sites, 108 N-linked glycans (4 sites), 13 O-linked glycans (45 sites).
DR   iPTMnet; O00468; -.
DR   PhosphoSitePlus; O00468; -.
DR   BioMuta; AGRN; -.
DR   jPOST; O00468; -.
DR   MassIVE; O00468; -.
DR   PaxDb; 9606-ENSP00000368678; -.
DR   PeptideAtlas; O00468; -.
DR   ProteomicsDB; 47914; -. [O00468-1]
DR   Pumba; O00468; -.
DR   Antibodypedia; 12009; 206 antibodies from 27 providers.
DR   DNASU; 375790; -.
DR   Ensembl; ENST00000379370.7; ENSP00000368678.2; ENSG00000188157.16. [O00468-6]
DR   GeneID; 375790; -.
DR   KEGG; hsa:375790; -.
DR   MANE-Select; ENST00000379370.7; ENSP00000368678.2; NM_198576.4; NP_940978.2. [O00468-6]
DR   UCSC; uc001ack.3; human. [O00468-1]
DR   AGR; HGNC:329; -.
DR   CTD; 375790; -.
DR   DisGeNET; 375790; -.
DR   GeneCards; AGRN; -.
DR   GeneReviews; AGRN; -.
DR   HGNC; HGNC:329; AGRN.
DR   HPA; ENSG00000188157; Low tissue specificity.
DR   MalaCards; AGRN; -.
DR   MIM; 103320; gene.
DR   MIM; 615120; phenotype.
DR   OpenTargets; ENSG00000188157; -.
DR   Orphanet; 98913; Postsynaptic congenital myasthenic syndromes.
DR   Orphanet; 98914; Presynaptic congenital myasthenic syndromes.
DR   VEuPathDB; HostDB:ENSG00000188157; -.
DR   eggNOG; KOG3509; Eukaryota.
DR   GeneTree; ENSGT00940000158337; -.
DR   HOGENOM; CLU_001582_1_0_1; -.
DR   InParanoid; O00468; -.
DR   OMA; QKCTICT; -.
DR   OrthoDB; 5983569at2759; -.
DR   PAN-GO; O00468; 4 GO annotations based on evolutionary models.
DR   PathwayCommons; O00468; -.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-HSA-2022928; HS-GAG biosynthesis.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-3560783; Defective B4GALT7 causes EDS, progeroid type.
DR   Reactome; R-HSA-3560801; Defective B3GAT3 causes JDSSDHD.
DR   Reactome; R-HSA-3656237; Defective EXT2 causes exostoses 2.
DR   Reactome; R-HSA-3656253; Defective EXT1 causes exostoses 1, TRPS2 and CHDS.
DR   Reactome; R-HSA-419037; NCAM1 interactions.
DR   Reactome; R-HSA-4420332; Defective B3GALT6 causes EDSP2 and SEMDJL1.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   Reactome; R-HSA-9820960; Respiratory syncytial virus (RSV) attachment and entry.
DR   Reactome; R-HSA-9833110; RSV-host interactions.
DR   Reactome; R-HSA-9913351; Formation of the dystrophin-glycoprotein complex (DGC).
DR   SignaLink; O00468; -.
DR   SIGNOR; O00468; -.
DR   BioGRID-ORCS; 375790; 11 hits in 1157 CRISPR screens.
DR   ChiTaRS; AGRN; human.
DR   GeneWiki; Agrin; -.
DR   GenomeRNAi; 375790; -.
DR   Pharos; O00468; Tbio.
DR   PRO; PR:O00468; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; O00468; protein.
DR   Bgee; ENSG00000188157; Expressed in right uterine tube and 188 other cell types or tissues.
DR   ExpressionAtlas; O00468; baseline and differential.
DR   GO; GO:0005604; C:basement membrane; IDA:UniProtKB.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045202; C:synapse; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0035374; F:chondroitin sulfate binding; ISS:UniProtKB.
DR   GO; GO:0002162; F:dystroglycan binding; ISS:UniProtKB.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; ISS:UniProtKB.
DR   GO; GO:0043236; F:laminin binding; TAS:UniProtKB.
DR   GO; GO:0033691; F:sialic acid binding; ISS:UniProtKB.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0045162; P:clustering of voltage-gated sodium channels; TAS:UniProtKB.
DR   GO; GO:0007213; P:G protein-coupled acetylcholine receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0007528; P:neuromuscular junction development; IBA:GO_Central.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; ISS:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISS:UniProtKB.
DR   GO; GO:0045887; P:positive regulation of synaptic assembly at neuromuscular junction; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0043113; P:receptor clustering; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   GO; GO:0050808; P:synapse organization; TAS:UniProtKB.
DR   CDD; cd00054; EGF_CA; 3.
DR   CDD; cd00055; EGF_Lam; 2.
DR   CDD; cd00104; KAZAL_FS; 9.
DR   CDD; cd00110; LamG; 3.
DR   FunFam; 2.10.25.10:FF:000692; Agrin; 1.
DR   FunFam; 3.30.60.30:FF:000013; Agrin; 1.
DR   FunFam; 3.30.60.30:FF:000016; Agrin; 1.
DR   FunFam; 3.30.60.30:FF:000032; Agrin; 1.
DR   FunFam; 2.10.25.10:FF:000228; agrin isoform X1; 1.
DR   FunFam; 2.40.50.120:FF:000008; agrin isoform X1; 1.
DR   FunFam; 2.10.25.10:FF:000095; Notch, isoform B; 1.
DR   FunFam; 2.60.120.200:FF:000031; NtA agrin; 1.
DR   FunFam; 3.30.60.30:FF:000019; NtA agrin; 1.
DR   FunFam; 3.30.70.960:FF:000001; NtA agrin; 1.
DR   FunFam; 2.10.25.10:FF:000134; Transmembrane agrin; 1.
DR   FunFam; 2.10.25.10:FF:000140; Transmembrane agrin; 1.
DR   FunFam; 2.60.120.200:FF:000027; Transmembrane agrin; 1.
DR   FunFam; 2.60.120.200:FF:000045; Transmembrane agrin; 1.
DR   FunFam; 3.30.60.30:FF:000008; Transmembrane agrin; 1.
DR   FunFam; 3.30.60.30:FF:000015; Transmembrane agrin; 1.
DR   FunFam; 3.30.60.30:FF:000018; Transmembrane agrin; 1.
DR   FunFam; 3.30.60.30:FF:000022; Transmembrane agrin; 1.
DR   FunFam; 3.30.60.30:FF:000024; Transmembrane agrin; 1.
DR   Gene3D; 2.40.50.120; -; 1.
DR   Gene3D; 2.60.120.200; -; 3.
DR   Gene3D; 3.30.60.30; -; 9.
DR   Gene3D; 2.10.25.10; Laminin; 5.
DR   Gene3D; 3.30.70.960; SEA domain; 1.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR003884; FacI_MAC.
DR   InterPro; IPR003645; Fol_N.
DR   InterPro; IPR002350; Kazal_dom.
DR   InterPro; IPR036058; Kazal_dom_sf.
DR   InterPro; IPR001791; Laminin_G.
DR   InterPro; IPR002049; LE_dom.
DR   InterPro; IPR050372; Neurexin-related_CASP.
DR   InterPro; IPR004850; NtA_dom.
DR   InterPro; IPR000082; SEA_dom.
DR   InterPro; IPR036364; SEA_dom_sf.
DR   InterPro; IPR008993; TIMP-like_OB-fold.
DR   PANTHER; PTHR15036:SF83; AGRIN; 1.
DR   PANTHER; PTHR15036; PIKACHURIN-LIKE PROTEIN; 1.
DR   Pfam; PF00008; EGF; 2.
DR   Pfam; PF00053; EGF_laminin; 2.
DR   Pfam; PF00050; Kazal_1; 1.
DR   Pfam; PF07648; Kazal_2; 8.
DR   Pfam; PF00054; Laminin_G_1; 3.
DR   Pfam; PF03146; NtA; 1.
DR   Pfam; PF01390; SEA; 1.
DR   PRINTS; PR00011; EGFLAMININ.
DR   SMART; SM00181; EGF; 7.
DR   SMART; SM00179; EGF_CA; 3.
DR   SMART; SM00180; EGF_Lam; 2.
DR   SMART; SM00057; FIMAC; 4.
DR   SMART; SM00274; FOLN; 5.
DR   SMART; SM00280; KAZAL; 9.
DR   SMART; SM00282; LamG; 3.
DR   SMART; SM00200; SEA; 1.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 3.
DR   SUPFAM; SSF57196; EGF/Laminin; 3.
DR   SUPFAM; SSF100895; Kazal-type serine protease inhibitors; 9.
DR   SUPFAM; SSF82671; SEA domain; 1.
DR   SUPFAM; SSF50242; TIMP-like; 1.
DR   PROSITE; PS00022; EGF_1; 6.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 4.
DR   PROSITE; PS01248; EGF_LAM_1; 1.
DR   PROSITE; PS50027; EGF_LAM_2; 2.
DR   PROSITE; PS51465; KAZAL_2; 9.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 3.
DR   PROSITE; PS51121; NTA; 1.
DR   PROSITE; PS50024; SEA; 1.
DR   neXtProt; NX_O00468; -.
DR   PharmGKB; PA24626; -.
DR   TreeFam; TF326548; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell membrane;
KW   Congenital myasthenic syndrome; Developmental protein; Differentiation;
KW   Disease variant; Disulfide bond; EGF-like domain; Extracellular matrix;
KW   Glycoprotein; Heparan sulfate; Laminin EGF-like domain; Membrane;
KW   Metal-binding; Phosphoprotein; Proteoglycan; Proteomics identification;
KW   Reference proteome; Repeat; Secreted; Signal; Synapse; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..29
FT                   /evidence="ECO:0000255"
FT   CHAIN           30..2068
FT                   /note="Agrin"
FT                   /id="PRO_0000007471"
FT   CHAIN           30..1102
FT                   /note="Agrin N-terminal 110 kDa subunit"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000421613"
FT   CHAIN           1103..2068
FT                   /note="Agrin C-terminal 110 kDa subunit"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000421614"
FT   CHAIN           1103..1863
FT                   /note="Agrin C-terminal 90 kDa fragment"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000421615"
FT   CHAIN           1864..2068
FT                   /note="Agrin C-terminal 22 kDa fragment"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000421616"
FT   DOMAIN          31..157
FT                   /note="NtA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00443"
FT   DOMAIN          191..244
FT                   /note="Kazal-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          264..319
FT                   /note="Kazal-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          337..391
FT                   /note="Kazal-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          408..463
FT                   /note="Kazal-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          484..536
FT                   /note="Kazal-like 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          540..601
FT                   /note="Kazal-like 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          607..666
FT                   /note="Kazal-like 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          699..752
FT                   /note="Kazal-like 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          793..846
FT                   /note="Laminin EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00460"
FT   DOMAIN          847..893
FT                   /note="Laminin EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00460"
FT   DOMAIN          917..971
FT                   /note="Kazal-like 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DOMAIN          1130..1252
FT                   /note="SEA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00188"
FT   DOMAIN          1329..1367
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1372..1548
FT                   /note="Laminin G-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          1549..1586
FT                   /note="EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1588..1625
FT                   /note="EGF-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1635..1822
FT                   /note="Laminin G-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   DOMAIN          1818..1857
FT                   /note="EGF-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1868..2065
FT                   /note="Laminin G-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00122"
FT   REGION          995..1096
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1277..1334
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1023..1042
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1050..1065
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1297..1318
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1321..1332
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         1940
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P25304"
FT   BINDING         1957
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P25304"
FT   BINDING         2007
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P25304"
FT   BINDING         2009
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P25304"
FT   SITE            1102..1103
FT                   /note="Cleavage, alpha site; by neurotrypsin"
FT                   /evidence="ECO:0000250"
FT   SITE            1250
FT                   /note="Alternative splice site to produce 'x' isoforms"
FT                   /evidence="ECO:0000250"
FT   SITE            1751
FT                   /note="Alternative splice site to produce 'y' isoforms"
FT                   /evidence="ECO:0000250"
FT   SITE            1862
FT                   /note="Critical for cleavage by neurotrypsin"
FT                   /evidence="ECO:0000250"
FT   SITE            1863..1864
FT                   /note="Cleavage, beta site; by neurotrypsin"
FT                   /evidence="ECO:0000250"
FT   SITE            1888
FT                   /note="Alternative splice site to produce 'z' isoforms"
FT                   /evidence="ECO:0000250"
FT   SITE            1892
FT                   /note="Highly important for the agrin receptor complex
FT                   activity of the 'z(8)' insert"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         674
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:A2ASQ1"
FT   MOD_RES         676
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:A2ASQ1"
FT   CARBOHYD        135
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        250
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        777
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        932
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1835
FT                   /note="O-linked (Fuc...) serine"
FT                   /evidence="ECO:0000250|UniProtKB:P25304"
FT   DISULFID        31..103
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00443"
FT   DISULFID        152..177
FT                   /note="Or C-152 with C-183"
FT   DISULFID        197..228
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        202..221
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        210..242
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        270..303
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        276..296
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        285..317
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        349..368
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        357..389
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        414..447
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        421..440
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        429..461
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        490..520
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        494..513
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        502..534
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        546..585
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        555..578
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        567..599
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        613..650
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        623..643
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        632..664
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        705..736
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        709..729
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        718..750
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        793..805
FT                   /evidence="ECO:0000250"
FT   DISULFID        795..812
FT                   /evidence="ECO:0000250"
FT   DISULFID        814..823
FT                   /evidence="ECO:0000250"
FT   DISULFID        826..844
FT                   /evidence="ECO:0000250"
FT   DISULFID        847..859
FT                   /evidence="ECO:0000250"
FT   DISULFID        849..866
FT                   /evidence="ECO:0000250"
FT   DISULFID        868..877
FT                   /evidence="ECO:0000250"
FT   DISULFID        880..891
FT                   /evidence="ECO:0000250"
FT   DISULFID        923..955
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        928..948
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        937..969
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00798"
FT   DISULFID        1333..1344
FT                   /evidence="ECO:0000250"
FT   DISULFID        1338..1355
FT                   /evidence="ECO:0000250"
FT   DISULFID        1357..1366
FT                   /evidence="ECO:0000250"
FT   DISULFID        1519..1548
FT                   /evidence="ECO:0000250"
FT   DISULFID        1553..1564
FT                   /evidence="ECO:0000250"
FT   DISULFID        1558..1574
FT                   /evidence="ECO:0000250"
FT   DISULFID        1576..1585
FT                   /evidence="ECO:0000250"
FT   DISULFID        1592..1603
FT                   /evidence="ECO:0000250"
FT   DISULFID        1597..1613
FT                   /evidence="ECO:0000250"
FT   DISULFID        1615..1624
FT                   /evidence="ECO:0000250"
FT   DISULFID        1822..1836
FT                   /evidence="ECO:0000250"
FT   DISULFID        1830..1845
FT                   /evidence="ECO:0000250"
FT   DISULFID        1847..1856
FT                   /evidence="ECO:0000250"
FT   DISULFID        2039..2065
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..104
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_045753"
FT   VAR_SEQ         105..154
FT                   /note="NQVSTGDTRIFFVNPAPPYLWPAHKNELMLNSSLMRITLRNLEEVEFCVE
FT                   -> MPXLAVARDTRQPAGASLLVRGFMVPCNACLILLATATLGFAVLLFLNNY (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_045754"
FT   VAR_SEQ         1752..1755
FT                   /note="Missing (in isoform 6 and isoform 7)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_045755"
FT   VAR_SEQ         1889..1907
FT                   /note="Missing (in isoform 3 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:9652404, ECO:0000303|Ref.1"
FT                   /id="VSP_045756"
FT   VAR_SEQ         1889..1896
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_045757"
FT   VAR_SEQ         1897..1907
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_045758"
FT   VARIANT         23
FT                   /note="V -> L"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068724"
FT   VARIANT         58
FT                   /note="D -> N"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068725"
FT   VARIANT         76
FT                   /note="G -> S (in CMS8; results in decreased AChR
FT                   clustering)"
FT                   /evidence="ECO:0000269|PubMed:24951643"
FT                   /id="VAR_071367"
FT   VARIANT         105
FT                   /note="N -> I (in CMS8; results in decreased AChR
FT                   clustering)"
FT                   /evidence="ECO:0000269|PubMed:19631309,
FT                   ECO:0000269|PubMed:24951643"
FT                   /id="VAR_068726"
FT   VARIANT         267
FT                   /note="T -> M"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068727"
FT   VARIANT         375
FT                   /note="A -> S (in dbSNP:rs138031468)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068728"
FT   VARIANT         728
FT                   /note="E -> V (in dbSNP:rs113288277)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068729"
FT   VARIANT         745
FT                   /note="A -> V"
FT                   /evidence="ECO:0000269|PubMed:24951643"
FT                   /id="VAR_071368"
FT   VARIANT         852
FT                   /note="Q -> R (in dbSNP:rs9697293)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068730"
FT   VARIANT         984
FT                   /note="V -> M"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068731"
FT   VARIANT         1088
FT                   /note="L -> F (in dbSNP:rs150132566)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068732"
FT   VARIANT         1118
FT                   /note="T -> K (in dbSNP:rs149159118)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068733"
FT   VARIANT         1135
FT                   /note="Q -> R (in dbSNP:rs142416636)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068734"
FT   VARIANT         1240
FT                   /note="P -> L (in dbSNP:rs142620337)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068735"
FT   VARIANT         1341
FT                   /note="G -> R"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068736"
FT   VARIANT         1451
FT                   /note="P -> L"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068737"
FT   VARIANT         1514
FT                   /note="A -> T (in dbSNP:rs111818381)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068738"
FT   VARIANT         1565
FT                   /note="Q -> H (in dbSNP:rs199876002)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068739"
FT   VARIANT         1666
FT                   /note="V -> I (in dbSNP:rs17160775)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_048966"
FT   VARIANT         1671
FT                   /note="R -> Q"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068740"
FT   VARIANT         1698
FT                   /note="R -> P"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068741"
FT   VARIANT         1709
FT                   /note="G -> R (in CMS8; results in disruption of the
FT                   neuromuscular junction architecture; does not affect
FT                   phosphorylation of MUSK; does not affect AChR clustering)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068742"
FT   VARIANT         1727
FT                   /note="V -> F (in CMS8; decreased AGRN-induced clustering
FT                   of AChR by >100-fold and decreased phosphorylation of the
FT                   MUSK receptor and AChR beta subunit by about 10-fold.
FT                   Increased binding to alpha-dystroglycan)"
FT                   /evidence="ECO:0000269|PubMed:22205389"
FT                   /id="VAR_069066"
FT   VARIANT         1734
FT                   /note="R -> H (in dbSNP:rs145444272)"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068743"
FT   VARIANT         1789
FT                   /note="D -> N"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068744"
FT   VARIANT         1875
FT                   /note="G -> R (in CMS8)"
FT                   /evidence="ECO:0000269|PubMed:24951643"
FT                   /id="VAR_071369"
FT   VARIANT         2046
FT                   /note="G -> V"
FT                   /evidence="ECO:0000269|PubMed:19631309"
FT                   /id="VAR_068745"
FT   CONFLICT        343
FT                   /note="L -> R (in Ref. 3; AAC39776)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   2068 AA;  217320 MW;  8B3E3D0FF65517F0 CRC64;
     MAGRSHPGPL RPLLPLLVVA ACVLPGAGGT CPERALERRE EEANVVLTGT VEEILNVDPV
     QHTYSCKVRV WRYLKGKDLV ARESLLDGGN KVVISGFGDP LICDNQVSTG DTRIFFVNPA
     PPYLWPAHKN ELMLNSSLMR ITLRNLEEVE FCVEDKPGTH FTPVPPTPPD ACRGMLCGFG
     AVCEPNAEGP GRASCVCKKS PCPSVVAPVC GSDASTYSNE CELQRAQCSQ QRRIRLLSRG
     PCGSRDPCSN VTCSFGSTCA RSADGLTASC LCPATCRGAP EGTVCGSDGA DYPGECQLLR
     RACARQENVF KKFDGPCDPC QGALPDPSRS CRVNPRTRRP EMLLRPESCP ARQAPVCGDD
     GVTYENDCVM GRSGAARGLL LQKVRSGQCQ GRDQCPEPCR FNAVCLSRRG RPRCSCDRVT
     CDGAYRPVCA QDGRTYDSDC WRQQAECRQQ RAIPSKHQGP CDQAPSPCLG VQCAFGATCA
     VKNGQAACEC LQACSSLYDP VCGSDGVTYG SACELEATAC TLGREIQVAR KGPCDRCGQC
     RFGALCEAET GRCVCPSECV ALAQPVCGSD GHTYPSECML HVHACTHQIS LHVASAGPCE
     TCGDAVCAFG AVCSAGQCVC PRCEHPPPGP VCGSDGVTYG SACELREAAC LQQTQIEEAR
     AGPCEQAECG SGGSGSGEDG DCEQELCRQR GGIWDEDSED GPCVCDFSCQ SVPGSPVCGS
     DGVTYSTECE LKKARCESQR GLYVAAQGAC RGPTFAPLPP VAPLHCAQTP YGCCQDNITA
     ARGVGLAGCP SACQCNPHGS YGGTCDPATG QCSCRPGVGG LRCDRCEPGF WNFRGIVTDG
     RSGCTPCSCD PQGAVRDDCE QMTGLCSCKP GVAGPKCGQC PDGRALGPAG CEADASAPAT
     CAEMRCEFGA RCVEESGSAH CVCPMLTCPE ANATKVCGSD GVTYGNECQL KTIACRQGLQ
     ISIQSLGPCQ EAVAPSTHPT SASVTVTTPG LLLSQALPAP PGALPLAPSS TAHSQTTPPP
     SSRPRTTASV PRTTVWPVLT VPPTAPSPAP SLVASAFGES GSTDGSSDEE LSGDQEASGG
     GSGGLEPLEG SSVATPGPPV ERASCYNSAL GCCSDGKTPS LDAEGSNCPA TKVFQGVLEL
     EGVEGQELFY TPEMADPKSE LFGETARSIE STLDDLFRNS DVKKDFRSVR LRDLGPGKSV
     RAIVDVHFDP TTAFRAPDVA RALLRQIQVS RRRSLGVRRP LQEHVRFMDF DWFPAFITGA
     TSGAIAAGAT ARATTASRLP SSAVTPRAPH PSHTSQPVAK TTAAPTTRRP PTTAPSRVPG
     RRPPAPQQPP KPCDSQPCFH GGTCQDWALG GGFTCSCPAG RGGAVCEKVL GAPVPAFEGR
     SFLAFPTLRA YHTLRLALEF RALEPQGLLL YNGNARGKDF LALALLDGRV QLRFDTGSGP
     AVLTSAVPVE PGQWHRLELS RHWRRGTLSV DGETPVLGES PSGTDGLNLD TDLFVGGVPE
     DQAAVALERT FVGAGLRGCI RLLDVNNQRL ELGIGPGAAT RGSGVGECGD HPCLPNPCHG
     GAPCQNLEAG RFHCQCPPGR VGPTCADEKS PCQPNPCHGA APCRVLPEGG AQCECPLGRE
     GTFCQTASGQ DGSGPFLADF NGFSHLELRG LHTFARDLGE KMALEVVFLA RGPSGLLLYN
     GQKTDGKGDF VSLALRDRRL EFRYDLGKGA AVIRSREPVT LGAWTRVSLE RNGRKGALRV
     GDGPRVLGES PKSRKVPHTV LNLKEPLYVG GAPDFSKLAR AAAVSSGFDG AIQLVSLGGR
     QLLTPEHVLR QVDVTSFAGH PCTRASGHPC LNGASCVPRE AAYVCLCPGG FSGPHCEKGL
     VEKSAGDVDT LAFDGRTFVE YLNAVTESEL ANEIPVPETL DSGALHSEKA LQSNHFELSL
     RTEATQGLVL WSGKATERAD YVALAIVDGH LQLSYNLGSQ PVVLRSTVPV NTNRWLRVVA
     HREQREGSLQ VGNEAPVTGS SPLGATQLDT DGALWLGGLP ELPVGPALPK AYGTGFVGCL
     RDVVVGRHPL HLLEDAVTKP ELRPCPTP
//
